Login to Your Account

AVI Starting Avicine Phase III To Speed Approval Timeline

By Karen Young

Friday, May 3, 2002
AVI BioPharma Inc. changed the course for its lead anticancer product, the vaccine Avicine, in an effort to shorten the route toward a possible FDA approval. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription